[1149] Amplification and Overexpression of HER-2/neu in Salivary Duct Carcinoma and Salivary Duct Carcinoma Ex Pleomorphic Adenoma of the Salivary Gland
M Urano, Y Kiriyama, Y Takakuwa, Y Mizoguchi, M Kuroda. Fujita Health University, School of Medicine, Toyoake, Aichi, Japan
Background: Salivary duct carcinoma (SDC) is an aggressive malignant tumor associated with high mortality. Recently, the indications for use of trastuzumab (Herceptin) as adjuvant therapy for SDC, similar to breast cancer, has been discussed. The object of this study is to clarify the relationship between HER-2/neu protein overexpression in immunohistochemistry (IHC) and gene amplification detected by fluorescence in situ hybridization (FISH) in SDC.
Design: We studied five cases of pure SDC and nine cases of SDC ex pleomorphic adenoma (PA) (13 male and 1 female, age 37 to 85, Ave. 62 yr) diagnosed between 1997 and 2007. Formalin-fixed, paraffin-embedded tissue from 14 cases were evaluated by IHC and FISH for HER-2/neu status.
Results: Of the 6 cases (43%) scored 3+ by IHC and all of them showed gene amplification by FISH. 4 cases (29%) scored 2+ and half of them showed amplification. 3 cases (21%) scored 1+ and 1 case (7%) scored 0 showed no amplification. 8 of 10 cases (80%) scored more than 2+ by IHC showed HER-2/neu gene amplification consequently.
table 1| case | histology | Age | Gender | Outcome | HER2-IHC | HER2-FISH | | 1 | SDC | 66 | M | Dead | 3+ | Amplified | | 2 | SDC | 85 | M | Dead | 0 | Not Amplified | | 3 | SDC | 60 | M | Dead | 3+ | Amplified | | 4 | SDC | 62 | M | Dead | 3+ | Amplified | | 5 | SDC | 78 | M | Dead | 2+ | Not Amplified | | 6 | SDC ex PA | 37 | M | Alive | 2+ | Amplified | | 7 | SDC ex PA | 77 | M | Alive | 1+ | Not Amplified | | 8 | SDC ex PA | 72 | M | Dead | 1+ | Not Amplified | | 9 | SDC ex PA | 55 | M | Alive | 2+ | Not Amplified | | 10 | SDC ex PA | 70 | M | Dead | 1+ | Not Amplified | | 11 | SDC ex PA | 55 | M | Dead | 2+ | Amplified | | 12 | SDC ex PA | 41 | F | Alive | 3+ | Amplified | | 13 | SDC ex PA | 66 | M | Alive | 3+ | Amplified | | 14 | SDC ex PA | 50 | M | Alive | 3+ | Amplified |
Conclusions: Clinically, most patients with SDC are in advanced stage and are metastasized when they visit clinics, and it is difficult to perform curable surgical treatment on them and some are inoperable. Our data demonstrate that Trastuzumab has a possibility of adjuvant therapy on the patients with FISH-positive HER-2/neu SDC and may play a role for improvement of their prognosis.
Category: Head & Neck
Monday, March 9, 2009 1:00 PM
Poster Session II # 154, Monday Afternoon
|